Test Code 602
Test Details
Lipoprotein-Associated Phospholipase A2 Activity [LpPLA2]
LpPLA2 is an enzyme produced by monocytes/macrophages that breaks down phospholipids. Increased blood levels of LpPLA2 are associated with soft, active growing plaque.*
*NOTE: Soft plaque is not stable calcified plaque.
Methodology
Enzyme Colormetric
Patient Preparation
None
Preferred Specimen
1.0 mL serum (0.5 mL minimum) collected in serum separator tube (SST/Tiger Top)
Alternate Specimen
None
Transport Temperature
Refrigerated (ship on frozen cold packs)
Stability
Refrigerated: 14 days
Lab Values
Lipoprotein-Associated Phospholipase A2 Activity [LpPLA2]
- Optimal: <180 nmol/min/mL
- Borderline: 180-224 nmol/min/mL
- Increased Risk: ≥225 nmol/min/mL
Clinical Significance
Lipoprotein-Associated Phospholipase A2 Activity [LpPLA2]
Predicts CVD risk independent of LDL-C and other inflammatory markers.1 Associated with:
- 2-fold increased risk for coronary events
- 2-fold increased risk for stroke
References:
- Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101(Suppl):51F-57F.
Treatment Options
Lipoprotein-Associated Phospholipase A2 Activity [LpPLA2]
- Lifestyle Modification
- Statins
- Omega-3 fatty acids (especially EPA)
- Combination therapy with statin and ezetimibe
